In March of 2018, ProteoFormiX became one of the first companies to become a resident of Johnson & Johnson Innovation, JLABS@BE, a premier life science incubator program.
As the first JLABS in Europe, JLABS @ BE accommodates life science start-ups focused on innovations across the entire healthcare spectrum, including pharmaceuticals, medical devices, consumer and health technology.
ProteoFormix is now officially a part of their portfolio.